

DRUG ALERT

CLASS 2 MEDICINES RECALL

Action within 48 Hours

Pharmacy and Wholesaler Level Recall

Dear Healthcare Professional

Sun Pharmaceutical Industries Europe BV

Zoledronic acid SUN 5mg solution for infusion

PL 31750/0054

Batch Number	Expiry Date	Pack Size	First Distributed
JKX5541B	11/2022	1x100ml vial	15-Jul-2021
HAC1087A	05/2023	1x100ml vial	15-Oct-2021
HAC3395A	08/2023	1x100ml vial	18-Mar-2022
HAD0156B	01/2024	1x100ml vial	17-May-2022

Active Pharmaceutical Ingredient: zoledronic acid (as monohydrate)

Brief description of the problem

Sun Pharmaceuticals are recalling the above batches of zoledronic acid due to out of specification results observed for Particulate Matter Test during routine stability testing.

This recall is conducted as a precautionary measure as remaining vials may no longer be in line with the licensed product specification with respect to particulate matter.

Advice for healthcare professionals

Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

If patients felt unwell after the administration of the affected batches above, please report this to the Marketing Authorisation Holder and complete a Yellow Card report via the MHRA [Yellow Card scheme](#).



Advice for patients

- Patients are not required to take any action at this time. This product is administered by healthcare professionals only. If you have concerns about zoledronic acid that has been given to you, please contact your healthcare professional.
- The Marketing Authorisation Holder has not received any reports of adverse reactions related to the issue above, however, patients who experience any adverse reactions should seek medical attention. These should also be reported via the MHRA [Yellow Card scheme](#).

Further Information

For more information, medical or supply enquiries, please contact Maciej Rosiak (Qualified Person), +31612091885; maciej.rosiak@sunpharma.com or Gene Kelleher (Head Quality Europe), +353 86 344 1145; gene.kelleher@sunpharma.com

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice.

RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter.

TO ALL CHEMISTS, DOCTORS ON THE LISTS

Pharmaceutical Services
2 Franklin Street
BELFAST
BT2 8DQ

Telephone No. 028 9536 0333

11th August 2022

Pharmaceutical website: <http://www.hscbusiness.hscni.net>